Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden

References

• Abrams, D. I., Steinhart, C., & Frascino, R. (2000). Epoetin alfa therapy for anaemia in HIV-infected patients: Impact on quality of life. International Journal of STD and AIDS, 11, 659–665. doi:10.1258/0956462001915020
   PubMed Web of Science ®Google Scholar
• Atkinson, M. J., & Petrozzino, J. J. (2009). An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care and STDs, 23, 903–914. doi:10.1089/apc.2009.0024
   PubMed Web of Science ®Google Scholar
• Bucciardini, R., Fragola, V., Massella, M., Polizzi, C., Mirra, M., Goodall, R., … Floridia, M. (2007). Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: The INITIO-QoL substudy. AIDS Research and Human Retroviruses, 23, 1215–1222. doi:10.1089/aid.2007.0067
   PubMed Web of Science ®Google Scholar
• Campo, R. E., Cohen, C., Grimm, K., Shangguan, T., Maa, J., & Seekins, D. (2010). Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients. International Journal of STD and AIDS, 21, 166–171. doi:10.1258/ijsa.2009.008487
   PubMed Web of Science ®Google Scholar
• Cella, D., Gilet, H., Viala-Danten, M., Peeters, K., Dubois, D., & Martin, S. (2010). Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. HIV Clinical Trials, 11(1), 18–27. doi:10.1310/hct1101-18
   PubMed Web of Science ®Google Scholar
• Clifford, D. B., Evans, S., Yang, Y., Acosta, E. P., Ribaudo, H., & Gulick, R. M. (2009). Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clinical Trials, 10, 343–355. doi:10.1310/hct1006-343
   PubMed Web of Science ®Google Scholar
• DeJesus, E., Ruane, P., McDonald, C., Garcia, F., Sharma, S., Corales, R., Flaherty, J. (2008). Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clinical Trials, 9(2), 103–114. doi:10.1310/hct0902-103
   PubMed Web of Science ®Google Scholar
• Gutierrez-Valencia, A., Viciana, P., Palacios, R., Ruiz-Valderas, R., Lozano, F., Terron, A., … Lopez-Cortes, L. F. (2009). Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: A randomized trial. Annals of Internal Medicine, 151, 149–156. doi:10.7326/0003-4819-151-3-200908040-00127
   PubMed Web of Science ®Google Scholar
• Hodder, S. L., Mounzer, K., Dejesus, E., Ebrahimi, R., Grimm, K., Esker, S., … Flaherty, J. F. (2010). Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care and STDs, 24(2), 87–96. doi:10.1089/apc.2009.0259
   PubMed Web of Science ®Google Scholar
• Journot, V., Chene, G., De Castro, N., Rancinan, C., Cassuto, J. P., Allard, C., … Molina, J. M. (2006). Use of efavirenz is not associated with a higher risk of depressive disorders: A substudy of the randomized clinical trial ALIZE-ANRS 099. Clinical Infectious Diseases, 42, 1790–1799. doi:10.1086/504323
   PubMed Web of Science ®Google Scholar
• Lafaurie, M., Collin, F., Bentata, M., Garre, M., Leport, C., Levy, Y., … Molina, J. M. (2008). Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: A substudy of the ANRS 099 ALIZE trial. Journal of Antimicrobial Chemotherapy, 62, 1122–1129. doi:10.1093/jac/dkn309
   PubMed Web of Science ®Google Scholar
• Nguyen, A., Calmy, A., Delhumeau, C., Mercier, I. K., Cavassini, M., Fayet-Mello, A., … Hirschel, B. (2011). A randomized crossover study to compare efavirenz and etravirine treatment. AIDS, 25(1), 57–63. doi:10.1097/QAD.0b013e32833f9f63
   PubMed Web of Science ®Google Scholar
• Nieuwkerk, P. T., & Oort, F. J. (2005). Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. Journal of Acquired Immune Deficiency Syndromes, 38, 445–448. doi:10.1097/01.qai.0000147522.34369.12
   PubMed Web of Science ®Google Scholar
• Potard, V., Chassany, O., Lavignon, M., Costagliola, D., & Spire, B. (2010). Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine. AIDS Care, 22, 54–61. doi:10.1080/09540120903033250
   PubMed Web of Science ®Google Scholar
• Saag, M. S., Bowers, P., Leitz, G. J., & Levine, A. M. (2004). Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients. AIDS Research and Human Retroviruses, 20, 1037–1045. doi:10.1089/aid.2004.20.1037
   PubMed Web of Science ®Google Scholar
• Simoni, J. M., Kurth, A. E., Pearson, C. R., Pantalone, D. W., Merrill, J. O., & Frick, P. A. (2006). Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS and Behavior, 10, 227–245. doi:10.1007/s10461-006-9078-6
   PubMed Web of Science ®Google Scholar
• Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. Journal of the American Medical Association, 273(1), 59–65. doi:10.1001/jama.1995.03520250075037
   PubMed Web of Science ®Google Scholar
• Wu, A. W., Snyder, C., Clancy, C. M., & Steinwachs, D. M. (2010). Adding the patient perspective to comparative effectiveness research. Health Affairs, 29, 1863–1871. doi:10.1377/hlthaff.2010.0660
   PubMed Web of Science ®Google Scholar